Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCC374 in Pulmonary Arterial Hypertension
2016-001412-38Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing QCC374 with Placebo (2 arms). Primary endpoint: Percentage of baseline pulmonary vascular resistance at week 16. Started Apr 2017; status: terminated.
02
Drugs
QCC374
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2016-001412-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001412-38.